JAMP CEFIXIME DIN 02572621
Health Canada record
| Active ingredient(s) | CEFIXIME 100 MG |
|---|---|
| Dosage form | Powder For Suspension |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01DD08 CEFIXIME |
| Original market date | |
| Current status date | 13-Oct-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating I (2026-09-16).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CEFIXIME
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02432773 | AURO-CEFIXIME | AURO PHARMA INC | Tablet | CEFIXIME 400 MG | Marketed |
| 02468689 | AURO-CEFIXIME | AURO PHARMA INC | Powder For Suspension | CEFIXIME 100 MG | Marketed |
| 00868981 | SUPRAX | ODAN LABORATORIESLTD | Tablet | CEFIXIME 400 MG | Marketed |
| 00868965 | SUPRAX | ODAN LABORATORIESLTD | Powder For Suspension | CEFIXIME 100 MG | Marketed |
| 02195992 | SUPRAX | AVENTIS PHARMA INC | Powder For Solution | CEFIXIME 100 MG | Cancelled Post Market |
| 00868973 | SUPRAX | SANOFI-AVENTIS CANADA INC | Tablet | CEFIXIME 200 MG | Cancelled Post Market |
| 02195984 | SUPRAX | AVENTIS PHARMA INC | Tablet | CEFIXIME 400 MG | Cancelled Post Market |
| 02195976 | SUPRAX - TAB 200MG | RHONE-POULENC RORER CANADA INC. | Tablet | CEFIXIME 200 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38465 | 2026-10-13 | Abbreviated New Drug Submission (ANDS) |
International API supply for CEFIXIME
11 active FDA Drug Master Files.
Request a quote for JAMP CEFIXIME